Johnson & Johnson Net Acquisitions/Divestitures 2012-2026 | JNJ
Johnson & Johnson annual/quarterly net acquisitions/divestitures history and growth rate from 2012 to 2026. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
- Johnson & Johnson net acquisitions/divestitures for the quarter ending March 31, 2026 were $-17.541B, a 15.81% increase year-over-year.
- Johnson & Johnson net acquisitions/divestitures for the twelve months ending March 31, 2026 were $-46.458B, a 0.96% decline year-over-year.
- Johnson & Johnson annual net acquisitions/divestitures for 2025 were $-17.541B, a 15.81% increase from 2024.
- Johnson & Johnson annual net acquisitions/divestitures for 2024 were $-15.146B, a 0% decline from 2023.
- Johnson & Johnson annual net acquisitions/divestitures for 2023 were $0B, a 100% decline from 2022.
|
Johnson & Johnson Annual Net Acquisitions/Divestitures (Millions of US $) |
|
|---|---|
| 2025 | $-17,541 |
| 2024 | $-15,146 |
| 2023 | N/A |
| 2022 | $-17,652 |
| 2021 | $-60 |
| 2020 | $-7,323 |
| 2019 | $-5,810 |
| 2018 | $-899 |
| 2017 | $-35,151 |
| 2016 | $-4,509 |
| 2015 | $-954 |
| 2014 | $-2,129 |
| 2013 | $-835 |
| 2012 | $-4,486 |
| 2011 | $-2,797 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |